返回 Agenda
Session Chair(s)
Richard Stephen Geary, PHD
Senior Vice President, Drug Development
Ionis Pharmaceuticals, Inc., United States
Jian Wang, PHD
VP
Bridgebio, United States
Speaker(s)
Clinical Pharmacology Considerations in Development of Antisense Oligonucleotide Based Therapeutics
Jian Wang, PHD
Bridgebio, United States
VP
Clinical Pharmacology Decisions in Early Development
Richard Stephen Geary, PHD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Drug Development
Animal to Human Dose Scaling for Oligonucleotides: Pertinent Factors
John S. Grundy, PHD
Ionis Pharmaceuticals, Inc., United States
Vice President, DMPK & Toxicology
A Question of Scale: Equating Oligonucleotide Doses Between Species
Ronald Wange, PHD
FDA, United States
Associate Director for Pharm/Tox OND